Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 72

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 72
---
 losses do not have an expiry date.

Going Concern - material uncertainty

The director’s considerations and judgement on going concern are set out in
note 1.

3 Revenue

Revenue from contracts with customers

Geographical analysis of revenue by destination of customer

  Schedule of revenue by geographical analysis                                                     
                                                    2024       2023                2022            
  Revenue:                                                                                         
  Belgium                                                                 381                 699  
                                                                          381                 699  

All revenue came from the sale of services in 2023 and 2022. It is derived entirely
from the Group’s R& D collaboration agreements. It is recognised over the contract term proportionate to the progress in overall
satisfaction of the performance obligations.

  Schedule of performance obligations                                                                                                                                                
                                                                                                 Contractual Assets      Contractual Liabilities                                     
                                                                                                 2024                    2024                                                        
  At 1 January                                                                                                                                        –            ( 197      –      
  Transfers in the period from contract assets to trade receivables                                                                                   –            –          –      
  Amounts included in contract liabilities that was recognised as revenue during the period                                                           –            197        –      
  Excess of revenue recognised over cash                                                                                                              –            –          –      
  Cash received in advance of performance and not recognised as revenue during the period                                                             ( 1,468      –          ( 197  
  At 31 December                                                                                                                                      ( 1,468      –          ( 197  

The Group’s R& D collaboration agreements are the delivery of services within
the next 12 months for which the practical expedient in paragraph 121 (a) of IFRS15 applies.

In 2024, no revenue from customers (2023: 1 customer; 2022: 1 customer).

  Schedule of commercial segment                                                              
                                      2024                2023                2022            
  Customer A                                     n/a                 100                 100  

The Group contains one reportable operating segment, Pipeline Research and Development
(‘ Pipeline R& D’). This segment seeks to develop products using the Group’s nanomedicine and sustained release technology
platforms. All the reconciliations required for segmental reporting can be found in the primary statements.

The accounting policies of the reportable segments are consistent with the Group’s
accounting policies described in note 1.

4 Loss from operations

  Schedule of loss from operations                                                                                                    
  Loss from operations is stated after charging/(crediting):